Authors
Latest:
Dr. Ioannou on Treatment Options in Hepatocellular CarcinomaGeorge N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.
Latest:
Dr. Kim on PRODIGE 37 in Pancreatic CancerGeorge P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.
Latest:
Dr. Blumenschein on Immunotherapy Combinations in NSCLCGeorge R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).
Latest:
Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLCGeorge R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.
Latest:
Dr. Simon on the Impact of Immunotherapy Agents in NSCLCGeorge R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.
Latest:
Dr. Sledge on Genomic Sequencing in Patients With Breast CancerGeorge Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.
Latest:
Dr. George Somlo on Treatment Considerations for Multiple MyelomaGeorge Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.
Latest:
Looking for a Therapeutic Edge Among CDK InhibitorsWhenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.
Latest:
Dr. Wiesner on Benefits of Genetic Testing in Colorectal CancerGeorgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.
Latest:
Dr Long on Unmet Needs in BRAF-Mutant MelanomaGeorgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.
Latest:
Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in MelanomaGeorgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.
Latest:
Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain MetsGeorgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.
Latest:
Dr. Falchook on TRK Alterations in Lung CancerGerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses TRK alterations in lung cancer.
Latest:
Factors Influencing Patient-Reported Rectal Toxicity Following External Beam Radiation Therapy for Prostate CancerDeveloping and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.
Latest:
Dr. Meinhardt on the Impact of the RESORCE Study in HCCGerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.
Latest:
Dr. Yadav on Differences in Type 1 and Type 2 Uterine CancerGhanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.
Latest:
Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCCGhassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.
Latest:
The Future of HCC TreatmentThe panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.
Latest:
Rapid Readouts: Final Results from Phase 3 ClarIDHy TrialGhassan K. Abou-Alfa, MD, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding final results from the ClarIDHy trial. In the phase 3 study, investigators examined ivosidenib vs placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation.
